BNP Paribas Asset Management
AUPH icon

BNP Paribas Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

BNP Paribas Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.3K Sell
1,430
-27
-2% -$431 ﹤0.01% 1996
2026
Q1 		$21.6K Buy
1,457
+215
+17% +$3.14K ﹤0.01% 2016
2025
Q4 		$20K Buy
1,242
+454
+58% +$6.44K ﹤0.01% 1955
2025
Q3 		$9K Buy
788
+149
+23% +$1.63K ﹤0.01% 1658
2025
Q2 		$5K Buy
+639
New +$5.12K ﹤0.01% 1977

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

BNP Paribas Asset Management's AUPH Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Aurinia Pharmaceuticals (AUPH) stake by 1.9% in Q2 2026, selling an estimated $431 and leaving 1,430 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1996.

BNP Paribas Asset Management first reported a position in AUPH in Q2 2025 and has held it in 5 quarters since. 208 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • BNP Paribas Asset Management held 1,430 shares of Aurinia Pharmaceuticals worth $24.3K as of Q2 2026.
  • BNP Paribas Asset Management sold 27 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $431.
  • Aurinia Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1996 holding.
  • BNP Paribas Asset Management first reported a position in Aurinia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 208 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.